Metizolam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Metizolam (desmethyletizolam) is a synthetic depressant of the thienotriazolodiazepine class. It is the N-desmethyl structural analog of etizolam, a pharmaceutical anxiolytic prescribed in Japan, Italy, and India. It amplifies the brain's primary calming signal — GABA — producing sedation, reduced anxiety, and muscle relaxation.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, thienodiazepines, zolpidem +2 morebenzodiazepines, thienodiazepines, zolpidem, zopiclone, zaleplon show less
The thienotriazolodiazepine class was first patented in Japan in 1975; metizolam was included but never developed as a medicine.[1][2][3] It surfaced on European research chemical markets in September 2015, sold as light blue tablets and powder by unregulated vendors. Metizolam remains unscheduled internationally, though the UK, Sweden, Germany, Canada, and several other countries have placed it under national control.
Subjective effects include sedation, anxiety suppression, muscle relaxation, memory gaps, and reduced mental sharpness. The experience is defined by what disappears — tension, anxiety, and edge — rather than any arrival of pleasure, and is less euphoric than most designer benzodiazepines.[4] Disinhibition, emotional suppression, and compulsive redosing are characteristic unwanted effects.
Metizolam can cause physical dependence with repeated use; taken alone, fatal overdose is rare.[5][3] The dominant danger is combination with opioids, alcohol, or other depressants — together they suppress breathing in ways that can kill, and standard hospital screens may not detect metizolam.[2] What is known comes almost entirely from one volunteer study and class-level inference.[6]
History[edit]
Discovery
The thienotriazolodiazepine class was first described in a 1975 patent filed in Japan.[1] Metizolam was included in that patent family but never selected for pharmaceutical development.[2][3] While etizolam became a prescribed anxiolytic in Japan, Italy, and India, metizolam stayed on the shelf for four decades.
Emergence as a designer drug
Metizolam appeared on European research chemical markets in September 2015, first identified in light blue tablets.citation needed The Swedish STRIDA project recorded four confirmed intoxication cases between 2012 and 2016.[7] The first controlled human data came from a single self-administration study.[6]
Present status
By 2020, twenty-nine designer benzodiazepines had been notified to European drug monitoring authorities.[8] Metizolam is among the least potent and least prominent, ranked alongside similar low-potency analogs in comparative assessments.[4] No clinical trials have been registered in any jurisdiction.
The name metizolam follows benzodiazepine naming convention — the "-zolam" suffix marks it as a thienotriazolodiazepine, and the "meti-" prefix distinguishes it from its parent compound Etizolam, referencing the desmethyl modification. In research chemical communities, metizolam attracted limited interest and has no street names or cultural identity independent of the designer benzodiazepine category.
Chemistry[edit]
Structural class
Metizolam belongs to the thienotriazolodiazepine class — a three-ring system in which a thiophene ring replaces the benzene ring found in classical benzodiazepines.[2] It differs from etizolam by the absence of a single methyl group. A 2-chlorophenyl group and an ethyl group complete the structure.[9]
The triazole ring fusion is associated with higher predicted GABA-A binding affinity compared to classical benzodiazepines.[10][3] Metizolam contains no chirality centers and exists as a single stereochemical form.
Molecular properties
| Molecular formula | C₁₆H₁₃ClN₄S |
| Molecular weight | 328.82 g/mol |
Pharmacology[edit]
Mechanism of action
Metizolam is a positive allosteric modulator of the GABA-A.[5][3] It doesn't activate GABA receptors directly. Instead, it binds alongside GABA — the brain's primary calming neurotransmitter — and amplifies its effect, producing sedation, reduced anxiety, muscle relaxation, and anticonvulsant activity.
No substance-specific binding data exist for metizolam. Its mechanism is inferred from its chemical structure, and confirmed indirectly by the finding that flumazenil — a drug that blocks benzodiazepine effects — reversed CNS depression in documented NPS benzodiazepine cases.[7]
Pharmacokinetics
Human data come from a single controlled study in one volunteer who took a 2 mg oral dose.[6] Metizolam is processed almost entirely by the liver — less than 0.3% appeared in urine unchanged,[6] with a urinary detection window of 46 hours. Standard benzodiazepine drug screens may not detect it; mass spectrometry is required for reliable identification.[2][3]
Neuroscience[edit]
Where it acts
Metizolam amplifies the brain's primary calming signal (GABA) across multiple regions. In the cortex, this reduces excitability and causes sedation and memory suppression.[11] In the amygdala, it dampens fear and anxiety; in the spinal cord, it relaxes muscles; at high doses or in combination with other depressants, brainstem suppression can slow or stop breathing.
Tolerance and neuroadaptation
With repeated use, the brain adapts: GABA receptors decrease in number and the excitatory glutamate system ramps up in response.[11] This produces tolerance, physical dependence, and a withdrawal when use stops. Tolerance to sedation builds faster than tolerance to anxiety suppression — so a person may still feel less anxious while needing higher doses to sleep.
No neuroimaging or electrophysiology studies have been conducted with metizolam. Key unknowns include whether the desmethyl modification alters the balance of effects relative to etizolam, and whether the primary metabolite is pharmacologically active — as alpha-hydroxyetizolam is for etizolam.
Subjective Effects[edit]
Metizolam produces the characteristic benzodiazepine quiet: anxiety recedes, physical tension releases, and mental sharpness dulls. The effect is one of subtraction — less presence of discomfort rather than the arrival of pleasure. Memory formation impairs during the experience, often without the user noticing.
Relative to etizolam, metizolam is less potent and less euphoric.[4] The profile sits closer to pyrazolam or deschloroetizolam — functional anxiety suppression with moderate sedation — than to heavily sedating designer benzodiazepines like flubromazolam or clonazolam.
Effect Grid
Clear anxiolysis dominates the experience, accompanied by moderate sedation and evident muscle relaxation. The characteristic benzodiazepine state is fully established — a dampening of cognitive sharpness, emotional reactivity, and physical tension.
Analysis suppression and thought deceleration are clearly present. Mild amnesia becomes possible, particularly for events occurring during the peak. Emotional suppression begins to flatten affect noticeably. Motor control impairment is evident in fine motor tasks and gait.
Disinhibition emerges at this tier, and delusions of sobriety may lead users to underestimate their level of impairment. Physical fatigue and drowsiness increase, particularly in the offset phase.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing suppression
Body high · Dizziness · Dry mouth · Nystagmus (eye wobbles) · Nausea
Nausea
Information processing suppression · Memory suppression · Analysis suppression · Cognitive euphoria · Thought deceleration · Language suppression · Memory fragmentation · Motivation suppression · Suggestibility enhancement · Compulsive redosing urge · Confusion · Thought disorganization · Humor enhancement · Amnesia · Delirium
Cognitive euphoria · Thought deceleration · Language suppression · Memory fragmentation · Motivation suppression · Compulsive redosing urge · Confusion · Thought disorganization · Humor enhancement · Amnesia · Delirium
Craving · Sociability suppression · Depersonalization · Derealization
Timeline
Gradual emergence of mild anxiolysis and subtle muscular relaxation. Effects may be difficult to distinguish from placebo at lower doses. The wide onset window (30–90 minutes) tempts premature redosing.
Deepening sedation and muscle relaxation become clearly perceptible. Anxiety suppression strengthens. Mild cognitive slowing begins.
Full anxiolysis, moderate-to-strong sedation, and cognitive suppression. Amnesia becomes possible at common doses and likely at strong doses. Disinhibition and emotional blunting are most pronounced.
Gradual return of baseline anxiety and cognitive function. Residual sedation and muscle relaxation persist. Motor coordination slowly recovers.
Residual drowsiness, mild cognitive fog, and possible rebound anxiety. Dreaming enhancement may occur during subsequent sleep.
⚠ Avoid driving or operating heavy machinery for at least 12 hours after use due to residual sedation and cognitive impairment.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severefatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · thienodiazepines · zolpidem
Toxicity
Benzodiazepines carry a wide safety margin when taken alone — oral overdose without other drugs rarely causes death.[5][3] No formal toxicity studies have been conducted for metizolam,safety citation needed and no metizolam-specific fatalities appear in the published literature. Four confirmed intoxication cases appeared in the Swedish STRIDA project between 2012 and 2016; all patients exposed to NPS benzodiazepines alone responded to flumazenil.[7]
Polysubstance lethality
The primary lethal risk is combining metizolam with other CNS depressants. Opioids and benzodiazepines suppress breathing through separate but complementary mechanisms — together the effect is greater than either alone.[2] Alcohol, barbiturates, gabapentinoids, GHB, and z-drugs each add to this respiratory and CNS depression.
Immunoassay detection gap
Standard hospital benzodiazepine screens may not detect metizolam.[2][3] Mass spectrometry is required for reliable identification.[6]
Product adulteration
Preparations from unregulated sources may be adulterated with opioids or other substances, mislabeled in dose or identity, or contain degradation products.[8][2] This elevates risk substantially beyond the pharmacological profile of the pure compound.
Psychological Risks
- Amnesia — Memory gaps are a core pharmacological effect, worsening with dose. Actions taken during intoxication may not be remembered, which becomes especially dangerous alongside disinhibition.
- Disinhibition — Benzodiazepines can produce paradoxical disinhibition, aggression, or risk-taking, particularly at higher doses or combined with alcohol.
- Delusions of sobriety — impairment is frequently underestimated, leading to dangerous decisions including driving, redosing, or adding other substances.
- Compulsive redosing — amnesia combined with impaired judgment creates a pattern where doses are repeated without awareness of prior doses.[8]
Designer benzodiazepines including metizolam have been identified as agents of drug-facilitated sexual assault due to their amnestic and sedating properties.[12]
Tolerance & Dependence
Tolerance develops through GABA-A downregulation,[11] with sedation tolerance building faster than anxiety-relief tolerance. Community reports suggest full tolerance reset takes approximately 1.5 weeks.safety citation needed Cross-tolerance exists with all benzodiazepine-site ligands — classical benzodiazepines, other thienodiazepines, and z-drugs (zolpidem, zopiclone, zaleplon).
Physical dependence can develop within weeks of daily use. Etizolam — the closest structural analog — has documented dependence cases.[13] Abrupt cessation carries seizure risk that may be life-threatening;safety citation needed gradual tapering under medical supervision is the standard approach.
Drug Interactions
All interaction data are inferred from benzodiazepine class pharmacology — no metizolam-specific interaction studies exist.
Opioids produce synergistic respiratory depression through complementary receptor mechanisms.[2] Alcohol potentiates both CNS and respiratory depression. Barbiturates, GHB/GBL, gabapentinoids (pregabalin, gabapentin), and z-drugs each carry additive or synergistic depressant risk.
Drugs that inhibit the liver enzyme CYP3A4 — including certain antifungals, antibiotics, and HIV medications — may raise metizolam blood levels by slowing its breakdown.[14]inferred CYP inducers such as carbamazepine may accelerate metabolism and reduce effects.[15]inferred
Contraindications
No metizolam-specific contraindication data exist. The following are inferred from benzodiazepine class pharmacology:
- Concurrent opioid use — Synergistic respiratory depression carries mortality risk.
- Concurrent alcohol intoxication — Additive CNS and respiratory depression.
- Respiratory insufficiency — Benzodiazepine-induced depression may precipitate respiratory failure.
- Severe liver impairment — Impaired clearance may prolong and intensify effects.inferred
- Pregnancy — Benzodiazepines cross the placenta and are associated with neonatal withdrawal.safety citation needed
- Myasthenia gravis — muscle relaxation may worsen neuromuscular weakness.
- History of substance use disorder — Elevated risk of dependence and compulsive use.
Flumazenil considerations: Flumazenil reversed CNS depression in documented NPS benzodiazepine intoxications.[7] However, it carries its own risks — including heart rhythm disturbances and convulsions — and a meta-analysis found significantly increased adverse events versus placebo.[16] Administration requires clinical judgment and is not a routine intervention.
Harm Reduction[edit]
Forms & Identification
Metizolam circulates exclusively through unregulated research chemical vendors. Reagent test kits cannot reliably distinguish between benzodiazepine analogs — a positive result confirms the class but not which compound. Drug-checking services offering FTIR or mass spectrometry provide the only reliable identity confirmation.
Given the documented risk of mislabeling and adulteration in designer benzodiazepine markets,[8] fentanyl test strips and analytical identity confirmation are both advisable before use.
Guidelines
- Start with the lowest available dose and wait at least 2 hours before considering redosing — onset and peak may be slower than expected.
- Use a milligram-precision scale for powder forms. Do not estimate doses by eye.
- Write down the time and amount of each dose before taking it. Amnesia makes mental tracking unreliable.
- Do not combine with opioids, alcohol, or other depressants under any circumstances.
- Do not drive or operate machinery.
- Inform a trusted person of the substance, dose, and timing.
- Set a hard limit on the total amount available for the session — remove excess supply from reach before dosing.
- Avoid daily or consecutive-day use. Physical dependence can develop within weeks.
Set & Setting
Benzodiazepines impair judgment, coordination, and memory formation. Use in an unfamiliar or unsafe environment increases the risk of injury and dangerous decisions. A trusted, sober companion reduces these risks significantly.
Avoid situations requiring motor coordination, driving, or consequential decision-making. Memory gaps mean actions during the experience may not be recalled — a safe, private environment is especially important.
Aftercare & integration. Residual sedation and cognitive dulling may persist for 12–24 hours after use. Allow adequate sleep and avoid demanding cognitive tasks the following day.
Review any notes or messages sent during the experience — amnesia may have obscured consequential actions or communications. If use was motivated by anxiety or insomnia, address the underlying condition through professional support rather than repeated self-medication.
Recovery & Support
Benzodiazepine dependence develops insidiously — what begins as occasional use can become daily reliance within weeks. If metizolam use has become regular, do not stop abruptly — withdrawal can produce life-threatening seizures. Gradual tapering under medical supervision is the safest approach to discontinuation.
Support resources include physicians experienced in benzodiazepine tapering, addiction medicine specialists, and peer support organizations. The Benzodiazepine Information Coalition (benzoinfo.com) and BenzoBuddies provide peer guidance and tapering protocols. SAMHSA's National Helpline (1-800-662-4357) offers free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, or stops
- Lips or fingertips turn blue
- Person is unresponsive to shouting or sternal rub
- Seizure activity
- Severe confusion or agitation beyond what the dose would explain
Immediate steps:
- 1. Call emergency services immediately if breathing is compromised or the person is unresponsive.
- 2. Place the person in the recovery position (on their side, airway clear).
- 3. Do not leave them alone.
- 4. Do not induce vomiting.
- 5. If opioid co-ingestion is suspected and naloxone is available, administer it — naloxone will not reverse benzodiazepine effects but will address the opioid component.
What to tell the dispatcher: Name the substance (metizolam or designer benzodiazepine), approximate dose and time taken, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Reversal agent: Flumazenil can reverse benzodiazepine-induced CNS depression but carries its own risks including seizures — its use is a clinical decision, not a field intervention.
Legal Status[edit]
Metizolam is not scheduled under any international convention. National status varies — several European nations and Canada have explicitly controlled it, while it remains unscheduled at the federal level in the United States.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not included in the 2025 DEA scheduling action that permanently controlled clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam. The Federal Analogue Act may apply if intended for human consumption. State laws vary.citation needed |
| United Kingdom | Class C, Schedule 1 | Controlled since May 2017 under the Misuse of Drugs Act 1971 (Amendment) Order 2017. Possession, production, supply, import, and export prohibited without authorization.[17] |
| Sweden | Controlled substance | Classified as a controlled substance on January 26, 2016.[9] |
| Germany | Controlled (NpSG) | Controlled under the New Psychoactive Substances Act since July 18, 2019. Permitted for industrial and scientific use only.citation needed |
| Canada | Schedule IV (CDSA) | All benzodiazepines are Schedule IV controlled substances under the Controlled Drugs and Substances Act.citation needed |
| Denmark | Controlled | Placed under national control; specific date not confirmed.citation needed |
| Finland | Controlled | Placed under national control; specific date not confirmed.citation needed |
| Australia | Likely Schedule 9 (unconfirmed) | Scheduling status not confirmed from primary sources.citation needed |
Legal status changes frequently and varies by jurisdiction. This information is provided for educational purposes and does not constitute legal advice. Verify current status through official sources before acting on it.
references
- [1]
- [2]
- [3]
- [4] ^abcEl Balkhi S, Monchaud C, Herault F, Geniaux H, Saint-Marcoux F (2020) Designer benzodiazepines' pharmacological effects and potencies: How to find the information — Journal of Psychopharmacology doi:10.1177/0269881119901096
- [5] ^abcBrunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP (2021) Designer Benzodiazepines: A Review of Toxicology and Public Health Risks — Pharmaceuticals doi:10.3390/ph14060560
- [6]